{"name":"Rivus Pharmaceuticals","slug":"rivus","ticker":"Private","exchange":"Private","domain":"rivuspharma.com","description":"Rivus Pharmaceuticals is a private company focused on developing treatments for obesity and metabolic disorders. The company has a pipeline of innovative therapies, including its lead product, Rivus-101, which is currently in Phase 3 clinical trials. Rivus Pharmaceuticals aims to address the growing need for effective and safe treatments for obesity and related metabolic conditions. With a strong pipeline and a focus on innovation, Rivus Pharmaceuticals is well-positioned to make a significant impact in the obesity and metabolic market.","hq":"New Haven, CT","founded":0,"employees":"","ceo":"Jayson Dallas","sector":"Obesity / Metabolic","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$1.5B valuation)","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Rivus-101 patent cliff ($1.5B at risk)","drug":"Rivus-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Rivus Pharmaceuticals Receives FDA Fast Track Designation for Rivus-101","summary":"Rivus Pharmaceuticals announced that the FDA has granted Fast Track designation to Rivus-101, its lead product for the treatment of obesity.","drugName":"Rivus-101","sentiment":"positive"},{"date":"2023-11-01","type":"earnings","headline":"Rivus Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Rivus Pharmaceuticals reported its third quarter 2023 financial results, with revenue of $10.2 million and a net loss of $25.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNd3ZtWTBZM2txV3paQlI0ZGE4VWJWNDhNcGZMRFNUSEdDZG9BX0FlX2hYeXdPOEFvWkxmU3BFZDZBelcwTlhZaWRiZ2UyYzFubjFPbGRrWUlYbEd6YzJiaERISTFwbkNTYXRLRk1paEh0R0Ridmg5ZmpHbFpPRkt5cDA0RUtTZ2FaenI4Z2NnaUU3dXRVeGFocQ?oc=5","date":"2025-11-04","type":"trial","source":"Yahoo Finance","summary":"Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek® - Yahoo Finance","headline":"Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selectiv","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxPOHFNQnZDQ2tfV2Z4M2o1TlpRQnhsZ1c2NUc0cWJBSVlYRm11bXhXanpMYkpsTF9iYlZoREhLXzItRmEyRUZuWkE2LTZTb1pvcXNkZ3FmbDNHeVdPQm1ld0c4akhvUkVncmUyS2hEQTRXbGJKWGs3QmtySWpxdlhFQUtvXzhrclloMzRiRzY2VUl1Q3E1MGNJR1dxd081ZUVWSEZjTnVERHlRMzl2dUJMMjhtWXhsaEJvektRRmlkNkUweG1tOWdoU0hTOUVWdW1mdUx0TUJ4czB1amRsQ29HQ3hNcWNhZjRwR3hkQUZhQ3VNenVBMHR6SFMtTi1iN19QVi1JbEZtZnp5dUFONWd6TlVuV09sNU9NajljMlp5d2w3U1hWX1JJcHkyMGVWVVJsRWdwNTdn?oc=5","date":"2025-10-14","type":"trial","source":"PR Newswire","summary":"Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025 - PR Newswire","headline":"Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNZHhLNm5rOWQ2TE12cHE3WFZvYzZWbDNpZmV4dGg5Q1p1a3RwM25wM09ZNVlxRVJWUE1JMDhTcS1nTzVOZXBIRTBLQ1ZIcDMyS1pIVFRJU0VjRUhzQnNOZGRwRU9DVG92MFRleVM3bEZVTVppRkpFbnlsTklBUkw1SFRiX2FhM2UxcEZ4UlZuM1d5b2ZPMnRoNGVOMEJKVF9fVzU3SGtFbC1ocUtRQWhRa29SS0lrVlV1T3dyRmg5cVZqY0tMNFN4elEwMkFiLXo4X3RpWGp6ai05aldqMEcwUlJ6NXJTWmN3d1dfMzVRY1ppY25RSHFMbko5NnVnSzdlSUpiU2R5YjZIcDlzYjV3WG5yVElQQVFwWWxiRUZUUnpoVmtydzVLbUlLdjdPcnBWYVd1VzN0VQ?oc=5","date":"2025-06-24","type":"trial","source":"PR Newswire","summary":"Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH - PR Newswire","headline":"Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reduction","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPN1QzeHo0RmpFeDNvWGZKdWFiek8tQmZISERlYlp5ZTFMRVo5Y2VoMkd4bEZSXzdtVU1sd0ZsM19kX2hmVnAtQkVTN1RvN3dVYTZtSXUzQUhqQkdYVm1UanNNT2FDamJEOEh6Q2YyRks0MFQ5NXh1WFNvQ05ITmtJQTJad04wc3F2SmFyR1NSeUJucEVlYmdfMGk1SldtNEh3Vk1rYnMyZnRrVm1TU2NubG5LaFJ4SWxLc2lidmstN09jQ0pLcTNYY2VwUEhBZFRFYmxfaG5QME8ya3hYRm84bTFKSVRGTS03NzRVeXMyS016Z19iRl9hQ3RKV003akdITVNKMVJfRkJLTnY1ejBMSk52bw?oc=5","date":"2025-04-10","type":"trial","source":"PR Newswire","summary":"Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Out in MASH - PR Newswire","headline":"Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Ou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNWFA4TWEwd1V3QXRfdUJQdEJfd1ZBcXM1REZZeWtzUVk2bDdoa01BQ2s0OFI1Z0ZvdERRbEp2MXlnTDdMQmIwM0V1cUx1cm5xUEVzM2lOWkszaUJxampFMnZoYWxwaU12cU5qR2FRNXJoanozZnhMbHhTbTAxZG1UelNNQ0ZrUnctOXQ5MFVCRXRiMk9GZkRxNVNLVXZhb2Q5R1ZHdkl1MGF4R0VsT2ctUjNDQUhnZkVXVzBaVlNNdk4tMlFWeWp0LWpDV0pMaXJVTEVER0t0TFp5VGFJakE?oc=5","date":"2025-01-08","type":"pipeline","source":"PR Newswire","summary":"Rivus Pharmaceuticals to Present Corporate Update at 2025 J.P. Morgan Healthcare Conference - PR Newswire","headline":"Rivus Pharmaceuticals to Present Corporate Update at 2025 J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNcFNTdlJ1ZUd3cXA2M01pSVVfT0l2NXJzVTZRUi02T2gxcUJoVnI1MVJXR2Q2dlZHaFBoVmdnWFdGanR4dG91NGJEaEVmWXY5a1NNa1FoeWg0YnBoTm5nRk00bjc4aUNFbjdJNGpHNnpwbERYUHJpUmJlUUp5emp1Tzc0ZzJLZFA0QmJiN0k0SEEtVVdHVElpa1paM2R5am45SlhWT3ZhdktOeWtrdEw4azNORQ?oc=5","date":"2024-10-07","type":"pipeline","source":"Bloomberg.com","summary":"Obesity Drugmaker Rivus Said to Weigh IPO as Soon as This Year - Bloomberg.com","headline":"Obesity Drugmaker Rivus Said to Weigh IPO as Soon as This Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNcFVkUklRQnVibUZnRHJXb1BQRGotMjcyajN3c015T0lCRXFMeXlFODd3b3pCNGFNWC10OU44cy1yQlE0RlA4ZDJMMDU1NXk3R0FqN0V0QkJrUHpab3NFSHB2MTJBUU05eWUyZV9IN2RTcnhBbjVWZk1Mc3hYUVFpeHJSLWtfemlsc1pUYTQzWUJjS0tUbnhzUGw0VFFoUGxJaFN5N1ZwdTdVTUZRUkx5Yk0wa3drU1dnb0FTZDJ4dDNYUHJ1QWxSbmdNSnphZG1BOHdVbzdQLTJQVTgzNWJBUDl3?oc=5","date":"2023-06-29","type":"pipeline","source":"PR Newswire","summary":"Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO - PR Newswire","headline":"Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQM3pPc29GbUVLcFpndllVQlZ3SVZFeWNSN3RBb1lES0RBTy02a0JkcGZyYTVfeXFabHpSaTZYZ2dkVGlPaWo4Q3J0ZGE3bGpwdm1CYVVFTGFQX0hBdGVjdHZuWkExY2t5Z0d2bXVqQUctdVlBRlV3OE5BOHpBVGlKd2NUWEFqQ05tUEFPN0JrV1hBUU5keWg0cnF3LTFlYVppazYxd2xDLTNwU3lLLWEwYkFSVEdnbEJqS0FDZjZGZ0pZbXdva0F2OEh3bEtneW02cm81QVRIbHR4NGhuZUgzSjVVbW9DV0J5S0tibE83dU0zZVVubVdNTGVOU25tdUNVNzFHM2wybUVaTHlqY0wtWDJtOE1BSGtNOFE?oc=5","date":"2022-09-22","type":"pipeline","source":"PR Newswire","summary":"Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders - PR Newswire","headline":"Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Meta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNS2sxdi1lQk1QNjNOUV9ZNVliZGJtbjBtVFBSVzVfN0cyX2VoNGtSSFk1OW9rMmJnb0RlRUxueWNXNkdnV3ZKTU5LaHFlYjF2T2pQNXhqM3cwbXJTZU1DZWRkWXB2T183MlpqbndIdTFPY0cwdy02dEFVMFRoSTB2WXVwYW5MMWhWWGh6R0UyaUtJMndPSnVtLU5BaXcwNmtQZWs0b01ld3FweE5ObGs4SUFDRmVnbW9ZTklXZDRpbGlaZXdBeU1VcGh6Znlyd09zZUZ2ZDR5MTFXb3BmQUlrMTFySDFoZFplRlhGS25VTVNMLTJpSHVUendrVGp4QTRHN05sNWk5eE9mM2gyYWZuWFpCR1ZaZkd5bWZhWHotcnFtQzhLUnRHT3lKWm9vQUo3YXpxRl9mUkJLUU9nMjhEMW01YktkTVpsOWQyV2hB?oc=5","date":"2021-11-01","type":"trial","source":"PR Newswire","summary":"Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardio-Metabolic Diseases - PR Newswire","headline":"Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficac","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNZ2hWazZ2ajFURUR1eWRnV0xkMGJEV1E2MFFfNjhDVlM0aXRxU3hISmNONk1vQmwzTXZnVEtOSVBsX19aYWtScDNWb1Itb1psUFpraDhpR1JyaHRJUXZObHFGVTRQRV9UNkpmTlRxd3dvWEtOWElXeHRHWXpFV2lKMzZJRFNlUWFhbVBzSDhOV3lIRDFieGVneC0tZ2VxOU9hTUxoRlFKTExyazJhbHZXdk13UTFsc0NMYmdQTWRXSG1ybDFqNzV4X2xtT0lCT3VzRU5Tc3F3NWVYQ2QwRzJCRWhQSE5KdDc1X3g0SnlGMElSN1czeEZ2MG9vLTRxN0ZMa1d4WThKM2ZTcEU?oc=5","date":"2021-07-20","type":"pipeline","source":"PR Newswire","summary":"Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases - PR Newswire","headline":"Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Dise","sentiment":"neutral"}],"patents":[{"drugName":"Rivus-101","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Novo Nordisk","Eli Lilly","Merck & Co."],"therapeuticFocus":["Obesity","Metabolic Disorders"],"financials":null,"yahoo":null}